Literature DB >> 7062375

Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

W Lutzeyer, H Rübben, H Dahm.   

Abstract

A retrospective study of 315 patients with superficial transitional cell carcinoma (stages Ta to T2) and an adequate followup of 3 years or longer is reported. Transurethral resection was done in 80 per cent of the patients and open excision or resection was done in 20 per cent for cure or control. We herein demonstrate that, in addition to grade and stage, multifocal tumor growth and whether the tumor is primary or recurrent influence the frequency of recurrences and tumor progression. The over-all recurrence rate after resection of stages Ta, T1 and T2 tumors within 3 years was 60 per cent. Recurrences after a primary tumor were noted in 45 per cent of the patients and were followed by a second recurrence in 84 per cent, with solitary tumors occurring in 46 and multifocal tumors in 73 per cent. Tumor progression was observed in 24 per cent of patients with solitary tumors, 44 per cent of those with multifocal tumors, 20 to 25 per cent of those with primary and recurrent stage Ta and primary stage T1 tumors, and 56 per cent of those with recurrent stage T1 tumors. Therefore, when therapy is planned stage, grade, multifocal tumor growth and whether the tumor is primary or recurrent should be considered. Stage Ta tumors can be treated sufficiently by transurethral resection even in the case of several recurrences. More aggressive therapy should be considered when multifocal or recurrent stage T1 or T2 tumors recur as invasive carcinomas.

Entities:  

Mesh:

Year:  1982        PMID: 7062375     DOI: 10.1016/s0022-5347(17)53725-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  60 in total

1.  Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.

Authors:  Wassim Kassouf; Ashish M Kamat; Alexander Zlotta; Bernard H Bochner; Ronald Moore; Alan So; Jonathan Izawa; Ricardo A Rendon; Louis Lacombe; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

2.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

3.  Long-term BCG immune therapy of superficial bladder tumours.

Authors:  L Somogyi; A Szántó; L Polyák; F Baranyay; M Drinóczy
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

Review 4.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

5.  Clinical studies on bladder tumor-associated antigen in serum of patients with bladder cancer by using monoclonal antibody and sandwich ELISA.

Authors:  S S Zhu; Y C Zhang; R Z Hu; Z Q Ye; C J Li; Q A Lin
Journal:  J Tongji Med Univ       Date:  1990

6.  The optimal management of T1 high-grade bladder cancer.

Authors:  Kenneth G Nepple; Michael A O'Donnell
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

Review 7.  Tumors of the kidney, ureter, and bladder.

Authors:  W A See; R D Williams
Journal:  West J Med       Date:  1992-05

Review 8.  Bladder cancer.

Authors:  H Y Leung; T R Griffiths; D E Neal
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

9.  Comparison of 30 mg and 40 mg of mitomycin C intravesical instillation in Korean superficial bladder cancer patients: prospective, randomized study.

Authors:  Chang Wook Jeong; Hwang Gyun Jeon; Cheol Kwak; Hyeon Jeong; Sang Eun Lee
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

Review 10.  Superficial bladder carcinoma. Factors affecting the natural history.

Authors:  J M Fitzpatrick
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.